Roivant Sciences Ltd. (ROIV) Stock Price & Analysis

Roivant Sciences Ltd. (ROIV) closed at USD 37.45 on Thursday, October 22, 2026, up 1.77% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 36.8; the Oct 22, 2026 session ranged USD 36.68–38.48 on volume of 13,451,164 shares. Market capitalization is $27.05B, with a 52-week range of USD 17.89–42.5 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:57 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ROIV.md

Key facts (ROIV)

• Last four reported quarters (through Jun 30, 2026): revenue $7.5M, net income -$266M (-3535.0% margin), free cash flow -$821M (SEC filings).
• 4 of 80 tracked superinvestors hold ROIV (13F, Q2 2026): 1 new, 1 added, 1 reduced, 1 unchanged.
• Analysts: Buy (mean 2.00 on a 1–5 scale) (13 analysts), mean target USD 48.91 (range 41–62).
• Total return with dividends: 1Y +106.7% vs S&P 500 +14.9%; 5Y +450.7% vs S&P 500 +80.3%.
• Next earnings: 2026-11-09, EPS estimate USD -0.45, revenue estimate $3.7M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ROIV)

Fiscal years end Mar. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ROIV)

P/S 3591.5x · P/B 6.4x · FCF yield -3.04% · Earnings yield -0.98%

P/E at fiscal year-ends: Mar 2024 2.0x.

Superinvestors (SEC 13F-HR, Q2 2026) (ROIV)

4 of 80 tracked investors hold ROIV. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (ROIV)

Consensus Buy (mean 2.00 on a 1–5 scale), 13 analysts; mean target USD 48.91 (low 41, high 62).

Rating changes, last 120 days:

Total return (dividends reinvested) (ROIV)

ROIV suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed May 20, 2026.

Companies that name ROIV in their SEC reports

ROIV company outlook (results filed Aug 6, 2026)

• “Major Upcoming Milestones • Priovant expects the commercial launch of brepocitinib in DM by the end of September 2026 and topline data from the Phase 3 study in NIU and Phase 3 study in CS in the second half of calendar year 2026 and calendar year 2028, respectively.”
• “Roivant continues to actively explore other indications for brepocitinib. • Immunovant expects to report topline data from the proof-of-concept trial of IMVT-1402 in CLE and provide an update on the potentially registrational program of IMVT-1402 in D2T RA in the second half of calendar year 2026.”
• “In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG.”
• “In calendar year 2028, topline data are expected across potentially registrational trials of IMVT-1402 in CIDP and SjD. • Pulmovant expects to report topline data from the ongoing Phase 2 trial of mosliciguat in PH-ILD in the second half of calendar year 2026. • Genevant LNP litigation continues to progress.”

Quoted word-for-word from the SEC 8-K results press release.

ROIV analyst estimates and revisions

ROIV options: expected move

Options price a move of about ±13.0% (±$4.90) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±6.9% on average.

30-day implied volatility 57.1% vs 35.8% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:57 UTC)

Technical Analysis (ROIV)

Nexqual's technical model rates ROIV "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:57 UTC.

Analyst Ratings (ROIV)

Wall Street analysts rate ROIV "Buy" based on 13 analysts, with a mean price target of USD 48.91 (range USD 41–62), per Nexqual as of October 23, 2026 at 09:57 UTC.

Earnings (ROIV)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:57 UTC.

Financials & Fundamentals (ROIV)

Source: Nexqual, October 23, 2026 at 09:57 UTC.

Financial Health Score (ROIV)

Nexqual rates Roivant Sciences Ltd.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:57 UTC.

Ownership (ROIV)

Source: Nexqual, October 23, 2026 at 09:57 UTC.

Leadership (ROIV)

Roivant Sciences Ltd. is led by Matthew Gline, CEO & Director, per Nexqual as of October 23, 2026 at 09:57 UTC.

Major Backers & Investors (ROIV)

Notable institutional backers of Roivant Sciences Ltd. include FMR, LLC, Morgan Stanley, Fidelity, according to Nexqual as of October 23, 2026 at 09:57 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:57 UTC.

From Roivant Sciences Ltd.'s Latest SEC 10-K Filing (filed 2026-05-20)

Key Strengths & Strategy (as disclosed to the SEC)

• The FDA accepted brepocitinib's New Drug Application ("NDA") in DM with Priority Review and assigned a target action date in the third quarter of calendar year 2026.
• IVIg also has a black box warning for serious risks, including thrombosis and kidney failure. •For patients with NIU who do not respond adequately to traditional therapies, adalimumab (HUMIRA) administered subcutaneously, is the only FDA-approved modern treatment.
• Under the HanAll Agreement, RSG received (1) the non-exclusive right to manufacture and (2) the exclusive, royalty-bearing right to develop, import, use and commercialize the antibody referred to as batoclimab and certain back-up and next-generation antibodies (including IMVT-1402), and products containing such antibodies in the U.S., Canada, Mexico, the E.U., the U.K., Switzerland, the Middle East, North Africa and Latin America (the "HanAll Licensed Territory").
• We centralize capital allocation decisions at the Roivant level, while distributing operational decisions to the Vants, allowing us to strategically deploy capital in high growth areas, regardless of potentially competing operational priorities. •Maintaining a diversified pipeline with various risk profiles: We have built a broad and differentiated pipeline that includes several drug candidates across different therapeutic areas, phases of development, modalities and geographies.

Partnerships

• HanAll may disagree with our interpretation of the agreement or our actions thereunder, and we may be unable to reach an agreement with HanAll regarding the future of batoclimab.
• In September 2021, our subsidiary Priovant Therapeutics, Inc. ("Priovant") entered into a license and collaboration agreement with Pfizer (the "Pfizer-Priovant License Agreement").

Legal & Regulatory Risks (Item 1A, quoted)

• Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.
• Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit the scope of any approved label or market acceptance following regulatory approval or result in significant negative consequences.
• Any regulatory approvals that we receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval or contain requirements for potentially costly post-marketing testing.
• We may develop product candidates for the treatment of conditions for which there is little clinical experience and, in some cases, use new endpoints or methodologies, and the FDA or other regulatory authorities may not consider the endpoints of these clinical trials to provide clinically meaningful results.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:57 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt